• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Smith-Gomez Janis

    10/17/23 4:07:48 PM ET
    $ANZU
    Blank Checks
    Finance
    Get the next $ANZU alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Smith-Gomez Janis

    (Last) (First) (Middle)
    C/O 4875 WHITE BEAR PARKWAY

    (Street)
    WHITE BEAR LAKE MN 55110

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Envoy Medical, Inc. [ COCH ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    10/15/2023
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (right to buy) $2.4 10/15/2023 A 25,000 (1) 10/15/2033 Class A Common Stock 25,000 $0 25,000 D
    Explanation of Responses:
    1. Options to purchase 6,250 shares vest on 10/15/2024, and the remaining 18,750 shares vest pro rata on the 15th of each month thereafter for 36 consecutive months.
    /s/ Andrew Nick as Attorney-in-Fact for Janis Smith-Gomez pursuant to Power of Attorney previously filed 10/17/2023
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $ANZU alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ANZU

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ANZU
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Taylor Glen A (Amendment)

    4/A - Envoy Medical, Inc. (0001840877) (Issuer)

    12/4/23 4:57:21 PM ET
    $ANZU
    Blank Checks
    Finance

    Lucas Brent T. bought $11,990 worth of shares (12,380 units at $0.97), increasing direct ownership by 11% to 120,831 units (SEC Form 4)

    4 - Envoy Medical, Inc. (0001840877) (Issuer)

    11/24/23 4:09:42 PM ET
    $ANZU
    Blank Checks
    Finance

    SEC Form 4 filed by Taylor Glen A

    4 - Envoy Medical, Inc. (0001840877) (Issuer)

    11/22/23 4:11:45 PM ET
    $ANZU
    Blank Checks
    Finance

    $ANZU
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Anzu Special Acquisition Corp I Stockholders Approve Business Combination with Envoy Medical Corporation

    Anzu Special Acquisition Corp I (the "Company") (NASDAQ: "ANZU," "ANZUU" and "ANZUW"), announced today that its stockholders voted to approve the Business Combination Agreement with Envoy Medical Corporation ("Envoy"), and the transactions contemplated thereby (the "Business Combination") at the Company's special meeting of stockholders held on September 27, 2023 (the "Special Meeting"). Pursuant to the Business Combination Agreement, Merger Sub will merge with and into Envoy, with Envoy surviving the merger as a wholly owned subsidiary of the Company (the "Merger"). Following the closing of the Merger (the "Closing"), the Company will be renamed "Envoy Medical, Inc.", which is referred t

    9/27/23 4:10:00 PM ET
    $ANZU
    Blank Checks
    Finance

    Anzu Special Acquisition Corp I Announces Adjournment of Special Meeting of Stockholders

    Anzu Special Acquisition Corp I (the "Company") (NASDAQ: "ANZU," "ANZUU" and "ANZUWS"), announced today that it convened and then adjourned, without conducting any other business, the Company's special meeting of stockholders (the "Special Meeting") held on February 9, 2023. The Special Meeting has been adjourned until 9:30 a.m., Eastern time, on February 21, 2023 (the "Adjourned Special Meeting"). The Adjourned Special Meeting will be held virtually via live webcast at https://web.lumiagm.com/274911563. The record date remains the close of business, Eastern Time, on January 17, 2023. At the Adjourned Special Meeting, stockholders will be asked to vote on a proposal to amend the Company's

    2/9/23 4:15:00 PM ET
    $ANZU
    Blank Checks
    Finance

    $ANZU
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Lucas Brent T. bought $11,990 worth of shares (12,380 units at $0.97), increasing direct ownership by 11% to 120,831 units (SEC Form 4)

    4 - Envoy Medical, Inc. (0001840877) (Issuer)

    11/24/23 4:09:42 PM ET
    $ANZU
    Blank Checks
    Finance

    $ANZU
    SEC Filings

    View All

    SEC Form S-1/A filed by Anzu Special Acquisition Corp I (Amendment)

    S-1/A - Envoy Medical, Inc. (0001840877) (Filer)

    2/14/24 9:17:12 PM ET
    $ANZU
    Blank Checks
    Finance

    SEC Form S-1 filed by Anzu Special Acquisition Corp I

    S-1 - Envoy Medical, Inc. (0001840877) (Filer)

    1/18/24 5:09:23 PM ET
    $ANZU
    Blank Checks
    Finance

    SEC Form 10-Q/A filed by Anzu Special Acquisition Corp I (Amendment)

    10-Q/A - Envoy Medical, Inc. (0001840877) (Filer)

    1/17/24 4:16:52 PM ET
    $ANZU
    Blank Checks
    Finance

    $ANZU
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Anzu Special Acquisition Corp I (Amendment)

    SC 13G/A - Envoy Medical, Inc. (0001840877) (Subject)

    2/12/24 4:30:47 PM ET
    $ANZU
    Blank Checks
    Finance

    SEC Form SC 13G/A filed by Anzu Special Acquisition Corp I (Amendment)

    SC 13G/A - Anzu Special Acquisition Corp I (0001840877) (Subject)

    2/13/23 12:29:11 PM ET
    $ANZU
    Blank Checks
    Finance

    SEC Form SC 13G filed by Anzu Special Acquisition Corp I

    SC 13G - Anzu Special Acquisition Corp I (0001840877) (Subject)

    2/14/22 2:25:31 PM ET
    $ANZU
    Blank Checks
    Finance